Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).

Niemantsverdriet E, Ribbens A, Bastin C, Benoit F, Bergmans B, Bier JC, Bladt R, Claes L, De Deyn PP, Deryck O, Hanseeuw B, Ivanoiu A, Lemper JC, Mormont E, Picard G, Salmon E, Segers K, Sieben A, Smeets D, Struyfs H, Thiery E, Tournoy J, Triau E, Vanbinst AM, Versijpt J, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2018;63(4):1509-1522. doi: 10.3233/JAD-171140.

2.

CFAI-Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument.

De Roeck EE, Dury S, De Witte N, De Donder L, Bjerke M, De Deyn PP, Engelborghs S, Dierckx E.

Int J Geriatr Psychiatry. 2018 Jul;33(7):941-947. doi: 10.1002/gps.4875. Epub 2018 Apr 10.

PMID:
29637620
3.

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort.

Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2018;63(1):373-381. doi: 10.3233/JAD-170927.

4.

An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease.

De Roeck A, Duchateau L, Van Dongen J, Cacace R, Bjerke M, Van den Bossche T, Cras P, Vandenberghe R, De Deyn PP, Engelborghs S, Van Broeckhoven C, Sleegers K; BELNEU Consortium.

Acta Neuropathol. 2018 Jun;135(6):827-837. doi: 10.1007/s00401-018-1841-z. Epub 2018 Mar 27.

5.

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.

Bjerke M, Engelborghs S.

J Alzheimers Dis. 2018;62(3):1199-1209. doi: 10.3233/JAD-170680.

6.

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.

Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B, Sieben A, Martin JJ, Cras P, De Deyn PP, Van Broeckhoven C, van der Zee J, Engelborghs S.

Alzheimers Res Ther. 2018 Mar 20;10(1):31. doi: 10.1186/s13195-018-0364-0.

7.

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study.

Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE.

Clin Chem. 2018 Jun;64(6):927-937. doi: 10.1373/clinchem.2017.283028. Epub 2018 Mar 9.

PMID:
29523639
8.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27.

PMID:
29076399
9.

The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.

Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, Verhaeghe J, Van den Bossche T, Van Mossevelde S, Goeman J, De Deyn PP, Mariën P, Versijpt J, Sleegers K, Van Broeckhoven C, Wyffels L, Albert A, Ceyssens S, Stroobants S, Staelens S, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2017;60(2):561-576. doi: 10.3233/JAD-170327.

10.

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.

De Vos A, Bjerke M, Brouns R, De Roeck N, Jacobs D, Van den Abbeele L, Guldolf K, Zetterberg H, Blennow K, Engelborghs S, Vanmechelen E.

BMC Neurol. 2017 Aug 30;17(1):170. doi: 10.1186/s12883-017-0945-8.

11.

Alzheimer's disease CSF biomarkers: clinical indications and rational use.

Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S.

Acta Neurol Belg. 2017 Sep;117(3):591-602. doi: 10.1007/s13760-017-0816-5. Epub 2017 Jul 27. Review.

12.

No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.

Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van den Bossche T, Van Mossevelde S, De Vil B, Sieben A, Martin JJ, Cras P, Goeman J, De Deyn PP, Van Broeckhoven C, van der Zee J, Engelborghs S.

Alzheimers Res Ther. 2017 Jul 14;9(1):49. doi: 10.1186/s13195-017-0275-5.

13.

Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.

Johansson P, Almqvist EG, Bjerke M, Wallin A, Johansson JO, Andreasson U, Blennow K, Zetterberg H, Svensson J.

J Alzheimers Dis. 2017;59(3):1017-1026. doi: 10.3233/JAD-170226.

PMID:
28697566
14.

Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report.

Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, Huisa B, Jonsson M, Kramberger MG, Lossi L, Malojcic B, Mehrabian S, Merighi A, Mukaetova-Ladinska EB, Paraskevas GP, Popescu BO, Ravid R, Traykov L, Tsivgoulis G, Weinstein G, Korczyn A, Bjerke M, Rosenberg G.

BMC Neurol. 2017 May 23;17(1):102. doi: 10.1186/s12883-017-0877-3. Review.

15.

Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study.

Hessen E, Eckerström M, Nordlund A, Selseth Almdahl I, Stålhammar J, Bjerke M, Eckerström C, Göthlin M, Fladby T, Reinvang I, Wallin A.

Dement Geriatr Cogn Dis Extra. 2017 Feb 2;7(1):1-14. doi: 10.1159/000454676. eCollection 2017 Jan-Apr.

16.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.

17.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.

18.

CSF YKL-40 and GAP-43 are related to suicidal ideation in older women.

Rymo I, Kern S, Bjerke M, Zetterberg H, Marlow T, Blennow K, Gudmundsson P, Skoog I, Waern M.

Acta Psychiatr Scand. 2017 Apr;135(4):351-357. doi: 10.1111/acps.12701. Epub 2017 Feb 17.

PMID:
28211584
19.

Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.

Somers C, Goossens J, Engelborghs S, Bjerke M.

Biomark Med. 2017 Feb;11(2):169-178. doi: 10.2217/bmm-2016-0276. Epub 2017 Jan 23. Review.

PMID:
28111962
20.

Being smart about writing SMART objectives.

Bjerke MB, Renger R.

Eval Program Plann. 2017 Apr;61:125-127. doi: 10.1016/j.evalprogplan.2016.12.009. Epub 2016 Dec 23.

PMID:
28056403
21.

Origin of the U87MG glioma cell line: Good news and bad news.

Allen M, Bjerke M, Edlund H, Nelander S, Westermark B.

Sci Transl Med. 2016 Aug 31;8(354):354re3. doi: 10.1126/scitranslmed.aaf6853.

PMID:
27582061
22.

A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.

Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2016 Aug 10;54(1):383-95. doi: 10.3233/JAD-151097.

PMID:
27567807
23.

Biology of the cardiac myocyte in heart disease.

Peter AK, Bjerke MA, Leinwand LA.

Mol Biol Cell. 2016 Jul 15;27(14):2149-60. doi: 10.1091/mbc.E16-01-0038. Review.

24.

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation.

Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K; IFCC Working Group on Standardization of CSF proteins (WG-CSF).

Clin Chim Acta. 2017 Apr;467:27-33. doi: 10.1016/j.cca.2016.05.014. Epub 2016 May 20. Review.

PMID:
27216941
25.

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H.

Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. Review.

PMID:
27068280
26.

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements.

Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Clin Chem Lab Med. 2016 Jul 1;54(7):1177-91. doi: 10.1515/cclm-2015-0733.

27.

Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.

Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, Börjesson-Hanson A, Östling S, Kern J, Skoog I.

J Alzheimers Dis. 2016;49(3):733-41. doi: 10.3233/JAD-150525.

PMID:
26484922
28.

T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study.

Hessen E, Nordlund A, Stålhammar J, Eckerström M, Bjerke M, Eckerström C, Göthlin M, Fladby T, Reinvang I, Wallin A.

J Alzheimers Dis. 2015;47(3):619-28. doi: 10.3233/JAD-150109.

PMID:
26401697
29.

Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Öhrfelt A, Stålhammar J, Eckerström M, Carlsson M, Olsson E, Göthlin M, Svensson J, Rolstad S, Eckerström C, Bjerke M.

J Cereb Blood Flow Metab. 2016 Jan;36(1):95-113. Review.

30.

Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway.

Lødrup Carlsen KC, Haahtela T, Carlsen KH, Smith A, Bjerke M, Wickman M, Keil T, Ballereau S, Bedbrook A, Bergström A, Nawjin MC, Pinart M, Skrindo I, Xu CJ, De Carlo G, Anto JM, Bousquet J.

Int Arch Allergy Immunol. 2015;167(1):57-64. doi: 10.1159/000431359. Epub 2015 Jul 15.

31.

The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up.

Wallin A, Nordlund A, Jonsson M, Lind K, Edman Å, Göthlin M, Stålhammar J, Eckerström M, Kern S, Börjesson-Hanson A, Carlsson M, Olsson E, Zetterberg H, Blennow K, Svensson J, Öhrfelt A, Bjerke M, Rolstad S, Eckerström C.

J Cereb Blood Flow Metab. 2016 Jan;36(1):114-31. Review.

32.

Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.

Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR Jr, Weiner MW, Arnold SE, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2015 Jul 14;85(2):144-53. doi: 10.1212/WNL.0000000000001738. Epub 2015 Jun 17.

33.

CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment.

Rolstad S, Jakobsson J, Sellgren C, Isgren A, Ekman CJ, Bjerke M, Blennow K, Zetterberg H, Pålsson E, Landén M.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1091-8. doi: 10.1016/j.euroneuro.2015.04.023. Epub 2015 May 5.

PMID:
26024928
34.

Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.

Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, Jack C Jr, Weiner M, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative Investigators.

JAMA Neurol. 2015 May;72(5):571-81. doi: 10.1001/jamaneurol.2014.4829.

35.

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, Olsson B, Zetterberg H, Blennow K, Pålsson E, Landén M.

J Psychiatry Neurosci. 2015 Jul;40(4):250-8.

36.

Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy.

Bjerke M, Jonsson M, Nordlund A, Eckerström C, Blennow K, Zetterberg H, Pantoni L, Inzitari D, Schmidt R, Wallin A.

Dement Geriatr Cogn Dis Extra. 2014 Oct 21;4(3):385-94. doi: 10.1159/000366119. eCollection 2014 Sep.

37.

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.

Rosén C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, Lladó A, Blennow K, Zetterberg H.

Dement Geriatr Cogn Dis Extra. 2014 Jul 31;4(2):297-304. doi: 10.1159/000362164. eCollection 2014 May.

38.

Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.

Eckerström C, Olsson E, Klasson N, Berge J, Nordlund A, Bjerke M, Wallin A.

J Alzheimers Dis. 2015;44(1):205-14. doi: 10.3233/JAD-141053.

PMID:
25201779
39.

FAK is required for tension-dependent organization of collective cell movements in Xenopus mesendoderm.

Bjerke MA, Dzamba BJ, Wang C, DeSimone DW.

Dev Biol. 2014 Oct 15;394(2):340-56. doi: 10.1016/j.ydbio.2014.07.023. Epub 2014 Aug 13.

40.

Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke.

Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerström C, Bokemark L, Wallin A.

J Cent Nerv Syst Dis. 2014 May 19;6:51-8. doi: 10.4137/JCNSD.S13821. eCollection 2014.

41.

Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome.

Portelius E, Hölttä M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, Herukka SK, Blennow K, Mattsson N.

Neuromolecular Med. 2014 Jun;16(2):510-6. doi: 10.1007/s12017-014-8302-1. Epub 2014 Apr 18.

PMID:
24740518
42.

Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.

Jakobsson J, Bjerke M, Ekman CJ, Sellgren C, Johansson AG, Zetterberg H, Blennow K, Landén M.

Neuropsychopharmacology. 2014 Sep;39(10):2349-56. doi: 10.1038/npp.2014.81. Epub 2014 Apr 3.

43.

Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment.

Rosenberg GA, Bjerke M, Wallin A.

Stroke. 2014 May;45(5):1531-8. doi: 10.1161/STROKEAHA.113.004534. Epub 2014 Apr 1. Review. No abstract available.

44.

7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier.

Saeed A, Floris F, Andersson U, Pikuleva I, Lövgren-Sandblom A, Bjerke M, Paucar M, Wallin A, Svenningsson P, Björkhem I.

J Lipid Res. 2014 Feb;55(2):313-8. doi: 10.1194/jlr.P044982. Epub 2013 Dec 8.

45.

Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease.

Sala Frigerio C, Lau P, Salta E, Tournoy J, Bossers K, Vandenberghe R, Wallin A, Bjerke M, Zetterberg H, Blennow K, De Strooper B.

Neurology. 2013 Dec 10;81(24):2103-6. doi: 10.1212/01.wnl.0000437306.37850.22. Epub 2013 Nov 8.

PMID:
24212398
46.

Effects of dietary supplementation of coriander oil, in canola oil diets, on the metabolism of [1-(14)C] 18:3n-3 and [1-(14)C] 18:2n-6 in rainbow trout hepatocytes.

Randall KM, Drew MD, Øverland M, Østbye TK, Bjerke M, Vogt G, Ruyter B.

Comp Biochem Physiol B Biochem Mol Biol. 2013 Sep;166(1):65-72. doi: 10.1016/j.cbpb.2013.07.004. Epub 2013 Jul 16.

PMID:
23867781
47.

A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.

Eckerström C, Olsson E, Bjerke M, Malmgren H, Edman A, Wallin A, Nordlund A.

J Alzheimers Dis. 2013;36(3):421-31. doi: 10.3233/JAD-122440.

PMID:
23635408
48.

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.

Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M.

Brain Res. 2013 Jun 4;1513:117-26. doi: 10.1016/j.brainres.2013.03.019. Epub 2013 Mar 27.

PMID:
23541617
49.

Cerebrospinal fluid biomarkers mirror rate of cognitive decline.

Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A.

J Alzheimers Dis. 2013;34(4):949-56. doi: 10.3233/JAD-121960.

PMID:
23313924
50.

Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.

Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, Lind K, Blennow K, Pantoni L, Inzitari D, Wallin A.

Dement Geriatr Cogn Disord. 2012;34(1):61-7. doi: 10.1159/000341576. Epub 2012 Aug 22.

PMID:
22922641

Supplemental Content

Loading ...
Support Center